Notice ID: b4349caa0f7448f1ac7962e8f7806008Award NoticeAwardedArchived
Award to SIRTEX MEDICAL, INC.
Awarded on June 25, 2026. Full description on SAM.gov.
Awarded tounder HT941026PE102 (source: SAM.gov award notice)• $21.2K
Overview
- Posted
- June 25, 2026
- Notice type
- Award Notice
- Set-aside
- No Set aside used
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY HCD WEST
- Last updated
- Oct 29, 2026
- First published
- Last updated on SAM.gov
- Award date
- Jun 25, 2026
- Award amount (SAM.gov award notice)
- $21.2K
Identifiers
- Solicitation number
- HT941026N0076
- Notice ID
- b4349caa0f7448f1ac7962e8f7806008
- Award number (PIID)
- HT941026PE102
Description
Notice of award of firm fixed price contract HT941026PE102, awarded sole source to SIRTEX MEDICAL, INC.
Award Overview
Award Number
HT941026PE102
Award Amount (SAM.gov award notice)
$21.2K
Award Date
Jun 25, 2026
Awardee
Awardee UEI
CWH2GM13A2V6
Awardee CAGE Code
45EE6
Original Solicitation
Notice ID: b4349caa0f7448f1ac7962e8f7806008
Posted Date: Jun 25, 2026
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- $182.2KSigned Jul 24, 2026
- $182.2KSigned Dec 15, 2025
- $182.2KSigned Dec 15, 2025
- $182.2KSigned Sep 30, 2025
- $19.4KSigned Mar 14, 2025
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Mariangela Monsalve
Documents
Showing 1 of 1 items
Document | Source | Agency | Posted Date | File Size | Actions | |
|---|---|---|---|---|---|---|
| Special Notice | DEFENSE HEALTH AGENCY (DHA) | Jun 25, 2026 | 102.04 KB |
Lifecycle
- 3Version 3Award NoticeArchivedCurrent
Award to SIRTEX MEDICAL, INC.
Other notices for this solicitation
- Special NoticeRelated noticeJun 23, 2026
Notice of Intent to Sole Source SIRTEX MEDICAL, INC
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
National Contract SPE2D2-23-D-0006 - Famotidine Related Notice: SPE2D2-22-R-0119 | - | Awarded | Open |
See attached Notice of Intent to Sole Source HT941027N0010 | - | Special Notice | 11/23/2026 |
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil | - | Market Research | 11/15/2026 |
Please see attached for the sources sought notice/market research survey and MPID. | - | Market Research | 11/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | - | Solicitation | 10/26/2026 |
Additional Details
Solicitation Number
HT941026N0076
Archive Date
Jul 10, 2026
Office Address
CAMP PENDLETON, CA, 92055